Tamoxifen fuels uterine cancer by activating the PI3K pathway, according to a new study, bypassing mutations normally required. Findings point to potential strategies to reduce risk while preserving the drug’s breast cancer benefits. The post How Tamoxifen Raises Uterine Cancer Risk—and a Path to Prevention appeared first on Inside Precision Medicine.
